SACITUZUMAB GOVITECAN RECEIVES POSITIVE CHMP OPINION AS 2L TREATMENT FOR ADULT PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER
SACITUZUMAB GOVITECAN RECEIVES POSITIVE CHMP OPINION AS 2L TREATMENT FOR ADULT PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER -- Recommendation is Based on the Phase 3 ASCENT Study Showing that Sacituzumab Go...